Skip to main content
Premium Trial:

Request an Annual Quote

Rosemary Mazanet, Peter Lassota

Premium
Rosemary Mazanet has joined the board of directors of Cellumen, the company said last week.
 
Mazanet is currently CEO of Breakthrough Therapeutics and acting CEO of Access Pharmaceuticals. She has previously served as CSO and general partner of Oracle Partners, and as director of clinical research at Amgen. Mazanet is also a member of the board of trustees of the University of Pennsylvania School of Medicine, and serves on the boards of several public companies including GTx and Aksys.
 

 
Caliper this week said that it has appointed Peter Lassota as divisional vice president of oncology.
 
At Caliper, Lassota will lead the R&D activities involved in oncology applications and the utilization of biophotonic imaging for developing biomarker research technologies. Lassota joins Caliper from the Novartis Institutes for Biomedical Research, where he led Novartis’ US oncology pharmacology unit. Lassota has also worked at Wyeth-Ayerst Research and the American Cyanamid Company. He has an MS in chemistry from the University of Warsaw and a PhD in biochemistry and biophysics from the Polish Academy of Sciences.

The Scan

Self-Reported Hearing Loss in Older Adults Begins Very Early in Life, Study Says

A JAMA Otolaryngology — Head & Neck Surgery study says polygenic risk scores associated with hearing loss in older adults is also associated with hearing decline in younger groups.

Genome-Wide Analysis Sheds Light on Genetics of ADHD

A genome-wide association study meta-analysis of attention-deficit hyperactivity disorder appearing in Nature Genetics links 76 genes to risk of having the disorder.

MicroRNA Cotargeting Linked to Lupus

A mouse-based study appearing in BMC Biology implicates two microRNAs with overlapping target sites in lupus.

Enzyme Involved in Lipid Metabolism Linked to Mutational Signatures

In Nature Genetics, a Wellcome Sanger Institute-led team found that APOBEC1 may contribute to the development of the SBS2 and SBS13 mutational signatures in the small intestine.